Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISHL HL Update 2021 | 1st-line therapies in Hodgkin lymphoma

Paul Jan Bröckelmann • 11 Mar 2021
ISHL HL Update 2021
Hodgkin Lymphoma Lymphoma Antibodies Brentuximab vedotin
HD21

Paul Jan Bröckelmann, MD, University Hospital of Cologne, Cologne, Germany, discusses innovative 1st-line therapies currently being evaluated in patients with Hodgkin lymphoma, the perspective of the German Hodgkin Study Group, including the ongoing HD21 trial (NCT02661503), as well as elderly patients with Hodgkin lymphoma, who represent an area of unmet need. This interview took place at the Update on Hodgkin Lymphoma 2021, a Virtual ISHL event.

More from Paul Jan Bröckelmann

2:32
The growing role of anti-PD1 inhibitors in the frontline treatment of HL
Paul Jan Bröckelmann • 17 Oct 2022
2:04
The importance of individualizing treatment approaches in HL to improve patient outcomes
Paul Jan Bröckelmann • 17 Oct 2022
2:27
Using Hodgkin lymphoma as a model for immuno-oncologic therapeutic approaches in other lymphomas
Paul Jan Bröckelmann • 17 Oct 2022
2:17
Recent clinical developments in the treatment landscape for older patients with HL
Paul Jan Bröckelmann • 17 Oct 2022

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals